Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14515833 | 0.78 | EPHX2 (0.41) | LMNAHTTEPHX2 | |
| SCHEMBL2780925 | 0.75 | LMNA (0.42) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL2491687 | 0.75 | LMNA (0.63) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL2785409 | 0.75 | LMNA (0.42) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL7091557 | 0.73 | RAB9A (0.59) | HTTKDM4EALDH1A1GAANPC1 | |
| SCHEMBL3808864 | 0.70 | LMNA (0.52) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL4517477 | 0.70 | LMNA (0.42) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL23566413 | 0.69 | LMNA (0.56) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL8079170 | 0.69 | HTT (0.55) | LMNAHTTKDM4EALDH1A1GAA | |
| SCHEMBL19308408 | 0.69 | LMNA (1.00) | LMNAHTTKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1138546-C | Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine | ʷ��˿�������ȳ�ķ����˾ | 2004-02-18 | — | — | CN | disclosed |
| EP-1314728-A1 | Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1264827-A1 | Process for the preparation of Tosylbenzylformamides | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6222036-B1 | REACTING 2-THIO-4-DIMETHYOXYMETHYL-PYRIMIDINE WITH ACETIC ACID AND CATALYTIC AMOUNT OF CONCETRATED SULFURIC ACID TO PRODUCE 2-THIOPYRIMIDINE ALDEHYDE | SMITHKLINE BEECHAM CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6218537-B1 | Process for making pyridyl and pyrimidine substituted imidazole compounds | SMITHKLINE BEECHAM CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0802908-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6150557-A | REACTING COMPOUND CONTAINING SECONDARY AMIDE GROUPS WITH BENZENESULFINIC ACID OR ITS DERIVATIVE IN PRESENCE OF ACID CATALYST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-21 | — | — | US | disclosed |
| US-6103936-A | REACTING ALDEHYDE, SULFIDE, SULFONE, OR SULFOXIDE WITH FORMAMIDE IN PRESENCE OF ACID CATALYST, AND OPTIONALLY A DEHYDRATING AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0802908-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-29 | — | — | EP | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997025047-A1 | NOVEL CYCLOALKYL SUBSTITUDED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996021654-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | LMNA 4808/4885HTT 4513/4885KDM4E 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.